Acumen
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
500 Airport Blvd Ste 100, Burlingame, Ca...Phone Number
(650) 558-8882Website
www.acumenllc.comRevenue
$67.9 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
3
1
3
1
1
About Acumen
Acumen conducts policy research in support of federal, state, and local health care and social policy programs. Acumen is headquartered in Burlingham, California.Explore more
Acumen Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Acumen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Acumen has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Acumen launches new products
Acumen, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Acumen has new funding data
Website visits: Recent activity has been detected on your website
Click to see if Acumen had a recent Job posting/layoffs
Earning: See what the market has to say on Acumen recently announced quarterly report
Check out if Acumen is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Acumen
Recommended Actions
Reach out to Masked Content who joined Acumen as Masked Content
Find more new buyers
Compare Similar Companies to Acumen
Compare insights from companies similar to Acumen, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Acumen is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Acumen is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Acumen.
Acumen Tech Stack
A closer look at the technologies used by Acumen
See more technologies
Most Recent Scoops
Project
Spending/Investment
Project
Spending/Investment
Project
Spending/Investment
Project
Spending/Investment
Facilities Relocation / Expansion
Acumen News & Media
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
NEWTON, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced new research at the 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference, taking place December 1-4, 2025, in San Diego and online. Results from a collaborative study with JCR Pharmaceuticals demonstratAcumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
NEWTON, Mass., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced that it will present new findings at the upcoming 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference taking place in San Diego. The presentations include Acumen’s recruitment strategies for its PhaseAcumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer’s Disease
NEWTON, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced that the first participant has been dosed in the open-label extension (OLE) portion of its Phase 2 ALTITUDE-AD clinical trial evaluating sabirnetug (ACU193) in people with early Alzheimer's disease.Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights
NEWTON, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today reported financial results for the third quarter of 2025 and provided a business update.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Acumen
Sign Up For FreeTo access detailed company insights
Acumen conducts policy research in support of federal, state, and local health care and social policy programs. Acumen is headquartered in Burlingham, California.... Read More
